Ingenious Med

Patient Encounter Software Platform

Ingenious Med holds a rare position as a heavily utilized, real-time point-of-care solution for clinicians, playing an important role in care coordination and data capture.

Background
When Council first invested in Ingenious Med, the company was a market leader in the hospitalist physician group segment, but did not have any for-profit health system enterprise customers.

Council Impact
Council facilitated more than 35 introductions to potential customers and key industry influencers, resulting in contracts with more than 50% of the for-profit US hospitals and a contract with the largest non-profit health system. Additionally, after we sold our ownership in IngeniousMed we committed to helping the company contract with a large health system target which we accomplished 6 months later.

In addition to directly driving revenue growth, CEO Council member Tom Givens joined the Board and had a significant impact on strategic direction, encouraging the company to view itself more broadly as a point-of-care solution for all care-givers rather than as a more narrow physician charge capture product. The resulting IM1 solution that was developed now accounts for most of the company’s revenue and is the primary driver of the company’s enterprise value. Tom previously was Founder and CEO of Healthcare Management Systems (now known as MedHost), which was a leading hospital information system company with over 600 hospital facilities in its customer base.

Results
Ingenious Med quadrupled revenue growth in three and a half years prior to be recapitalized by Guidepost Growth Equity in 2014. At exit, Ingenious Med was the clear market leader in its market and had dramatically expanded its market opportunity through the launch of its flagship solution IM1, making it the premier patient encounter platform.

The CEO Council model helped drive a significant portion of that growth, and revenue under contract associated with Council introductions was 26% of revenue at the time of exit.